- Aktuelle Seite:
-
Home
-
Substanzen
-
Cannabis
-
Cannabis als Rauschmittel
- Cannabis und Schadensminderung in Deutschland - Cannabis and Harm Reduction in Germany
Chinese tombs yield earliest evidence of cannabis use
Researchers have uncovered the earliest known evidence of cannabis use, from tombs in western China.
The study suggests cannabis was being smoked at least 2,500 years ago, and that it may have been associated with ritual or religious activities. (BBC, 13.06.2019)
https://www.bbc.com/news/science-environment-48624784
Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity.
Wall, M. B., Pope, R., Freeman, T. P., Kowalczyk, O. S., Demetriou, L., Mokrysz, C., … Curran, H. V. (2019).
Journal of Psychopharmacology. doi.org/10.1177/0269881119841568
Abstract
https://journals.sagepub.com/doi/10.1177/0269881119841568
GDS2019: Cannabis health information labels: why it’s time to have mandatory warnings as part of any legal cannabis market and how they’ll help keep the cannabis industry on the straight and narrow.
Professor Adam R Winstock Consultant Psychiatrist & Founder, Global Drug Survey, Mai 2019
Quantifying hepatic enzyme kinetics of (-)-Δ9-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling
Gabriela I. Patilea-Vrana and Jashvant D. Unadkat
Drug Metabolism and Disposition May 2, 2019, dmd.119.086470; doi.org/10.1124/dmd.119.086470
http://dmd.aspetjournals.org/content/dmd/early/2019/05/02/dmd.119.086470.full.pdf
Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.
Farooqui MT, Khan MA, Cholankeril G, Khan Z, Mohammed Abdul MK, Li AA, Shah N, Wu L, Haq K, Solanki S, Kim D, Ahmed A.
Eur J Gastroenterol Hepatol. 2019 Feb;31(2):149-156. doi: 10.1097/MEG.0000000000001263.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467701/
The relationship between motivations for cannabis consumption and problematic use.
Casajuana Kögel C, López-Pelayo H, Oliveras C, Colom J, Gual A, Balcells-Oliveró MM.
Adicciones. 2019 Apr 8;0(0):1221. doi: 10.20882/adicciones.1221. [Epub ahead of print] English, Spanish.
http://adicciones.es/index.php/adicciones/article/view/1221
CBD reduces impairment caused by cannabis
The more cannabidiol (CBD) in a strain of cannabis, the lower the impairment to brain function, according to a new UCL-led brain imaging study. (UCL – University College London, 25.04.2019)
https://www.ucl.ac.uk/news/2019/apr/cbd-reduces-impairment-caused-cannabis
Cannabis Use Disorder.
Patel J, Marwaha R.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Feb 11. PMID: 30844158
https://www.ncbi.nlm.nih.gov/books/NBK538131/
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.
Solowij N, Broyd S,Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30661105 Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R.
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35. doi: 10.1007/s00406-019-00978-2.
https://www.ncbi.nlm.nih.gov/pubmed/30661105
CBD kann die Wirkung von THC verstärken
Bislang nahm man an, dass der Cannabisbestandteil Cannabidiol (CBD) keine psychoaktive Wirkung hat und den Effekt des Wirkstoffs THC abmildert. Einer experimentellen Studie zufolge müssen beide Annahmen korrigiert werden. (drugcom.de, 06.03.2019)
https://www.drugcom.de/?id=aktuelles&idx=1210
Cannabisrauchen in Maßen könnte sich auf Spermien auswirken
Boston – Ein geringer Cannabiskonsum könnte sowohl eine höhere Spermienzahl zufolge haben als auch höhere Testosteronwerte. Das ergab eine Beobachtungsstudie mit fast 700 Männern, die in Human Reproduction veröffentlicht wurde (2019; doi: 10.1093/humrep/dez002). Einen kausalen Zusammenhang konnten die Studienautoren allerdings nicht nachweisen. (aerzteblatt.de, 07.02.2019)
Pharmacotherapies for cannabis dependence.
Nielsen S, Gowing L, Sabioni P, Le Foll B.
Cochrane Database Syst Rev. 2019 Jan 28;1:CD008940. doi: 10.1002/14651858.CD008940.pub3.
Abstract
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008940.pub3/full
New trends in cannabis potency in USA and Europe during the last decade (2008-2017).
Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA.
Eur Arch Psychiatry Clin Neurosci. 2019 Jan 22. doi: 10.1007/s00406-019-00983-5.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30671616
Observations: Is Cannabis Good or Bad for Mental Health? The evidence says it can go either way.
(...) The reality is that cannabis cannot be pigeonholed as strictly helpful or harmful. Instead, meaningful discussion about its potential benefits and harms requires careful and nuanced consideration of the scientific literature, coupled with a humble attitude. As delineated in a recent and thorough review paper in the International Review of Psychiatry,the relationship between cannabis and mental health is especially complicated. (Scientific American, 17.01.2019)
https://blogs.scientificamerican.com/observations/is-cannabis-good-or-bad-for-mental-health/
Studie Cannabis-Produkte werden immer stärker
Der THC-Gehalt von Haschisch und Marihuana hat in den letzten Jahren drastisch zugenommen - bei gleichbleibendem Preis. Das birgt erhebliche gesundheitliche Risiken. (Spiegel online, 30.12.2018)
Increasing potency and price of cannabis in Europe, 2006-2016
Tom P. Freeman, Teodora Groshkova, Andrew Cunningham, Roumen Sedefov, Paul Griffiths, Michael T. Lynksey
Addiction, First published: 29 December 2018, doi.org/10.1111/add.14525
https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14525
WHO: Die Übersicht zu Cannabis bleibt unter Verschluss
Die mit Spannung für den 7. Dezember erwartete Veröffentlichung der Ergebnisse der zweijährigen wissenschaftlichen Bewertung von Cannabis, das „Critical Review on Cannabis“, im Rahmen des CND-Treffens (Commission on Narcotic Drugs) in Wien, fand nicht statt. Die letzte Einschätzung der WHO aus dem Jahr 1954 hatte das weltweite Verbot im Rahmen des UNO-Drogenkontrollvertrags gestärkt.
Als es an der Zeit war, die Ergebnisse im überfüllten Saal zugänglich zu machen, waren alle verblüfft, zu erleben, wie der Sprecher der WHO bekannt gab, dass das Ergebnis zu Cannabis vertraulich bleibt, und nicht einmal einen weiteren Termin für die Veröffentlichung nannte. Sprecher von Nicht-Regierungs-Organisationen kritisierten, dass die WHO sich nicht an ihre eigenen Regeln und Richtlinien halte. (IACM, 22.12.2018)
http://www.cannabis-med.org/german/bulletin/ww_de_db_cannabis_artikel.php?id=553#1
WHO. „...the outcome on Cannabis was kept confidential“
Vienna, UN headquarters. World Health Organization (WHO) much anticipated release of findings of two year scientific assessment of Cannabis leaves observers stunned and upset.The last assessment by WHO in 1954 fuelled global prohibition under the UN drug control Treaty framework. (FAAAT think & do tank, 07.12.2018)
http://conference.faaat.net/blog/press-statement-faaat-think-do-tank
Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial
D'Souza, Deepak Cyril et al.
The Lancet Psychiatry , Volume 0 , Issue 0 , online first, Published:December 06, 2018, doi.org/10.1016/S2215-0366(18)30427-9
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30427-9/fulltext
Cannabis Systematics at the Levels of Family, Genus, and Species.
McPartland JM.
Cannabis Cannabinoid Res. 2018 Oct 1;3(1):203-212. doi: 10.1089/can.2018.0039.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225593/
The Crimson Digest (Volume 1): Briefing on the international scientific assessment of cannabis: Processes, stakeholders and history
FAAAT, 2018
http://faaat.net/wp-content/uploads/CRIMSONDIGESTvol1_web.pdf
DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults.
Livne O, Shmulewitz D, Lev-Ran S, Hasin DS.
Drug Alcohol Depend. 2018 Oct 16. pii: S0376-8716(18)30714-2. doi: 10.1016/j.drugalcdep.2018.09.005.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30361043
A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age.
Sexton M, Cuttler C, Mischley LK.
J Altern Complement Med. 2018 Oct 31. doi: 10.1089/acm.2018.0319.
https://www.liebertpub.com/doi/full/10.1089/acm.2018.0319
Reduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume Cannabis.
Adejumo AC, Adegbala OM, Adejumo KL, Bukong TN.
Can J Gastroenterol Hepatol. 2018 Sep 23;2018:9430953. doi: 10.1155/2018/9430953.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174743/
Studie: Cannabisabstinenz verbessert verbales Gedächtnis von Jugendlichen
Boston – Der Verzicht auf einen Cannabiskonsum hat in einer randomisierten Studie das verbale Gedächtnis von Jugendlichen verbessert. Die Erholung trat laut der Publikation im Journal of Clinical Psychiatry(2018; 79: 17m11977) bereits in der ersten Woche der Abstinenz auf. (aerzteblatt.de, 31.10.2018)
People who gave up smoking cannabis had a memory boost within a week
Cannabis use really does weaken your memory. People who gave up smoking the drug saw their cognitive abilities improve after just a week. (New Scientist, UK, 30.10.2018)
Driving While Stoned: Issues and Policy Options
Mark A.R. Kleiman / Tyler Jones / Celeste J. Miller / Ross Halperin
Journal of Drug Policy Analysis, Online erschienen: 24.10.2018, doi.org/10.1515/jdpa-2018-0004
https://www.degruyter.com/view/j/jdpa.ahead-of-print/jdpa-2018-0004/jdpa-2018-0004.xml
WHO. WHO Expert Committee on Drug Dependence -- Critical Review: Cannabis and cannabis resin
WHO 2018
https://www.who.int/medicines/access/controlled-substances/Cannabis-and-cannabis-resin.pdf
How long does cannabis impairment last? Researchers are starting to find out
If rules about cannabis consumption for Canadian police are any measure, we know precious little about how long cannabis impairment lasts. The wait time for police to show up for work after consumption ranges anywhere from the next day to 28 days, with some forces prohibiting members from using the drug altogether.
University of Alberta psychiatrist Scot Purdon agrees the science is scant on impairment beyond the first few hours. (medicalxpress.com, USA, 18.10.2018)
https://medicalxpress.com/news/2018-10-cannabis-impairment.html
Editorial: Watching Canada’s experiment with legal cannabis
Diane Kelsall
CMAJ October 15, 2018 190 (41) E1218; DOI: https://doi.org/10.1503/cmaj.181287
On Oct. 17, 2018, the government of Canada will launch a national, uncontrolled experiment in which the profits of cannabis producers and tax revenues are squarely pitched against the health of Canadians. When Bill C-45 comes into force in mid-October, access to recreational marijuana will be legal 1 making Canada one of a handful of countries to legalize recreational use of the drug. Given the known and unknown health hazards of cannabis,2,3 any increase in use of recreational cannabis after legalization, whether by adults or youth, should be viewed as a failure of this legislation. The government of Canada should commit to amending the act if cannabis use rises.
http://www.cmaj.ca/content/190/41/E1218
Seite 1 von 5